New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.
New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a known cancer testis gene with exceptional immunogenicity and prevalent expression in many cancer types. These characteristics have made it an appropriate vaccine candidate with the potential application against various malignancies. This article reviews recent knowledge about the NY-ESO-1 biology, function, immunogenicity and expression in cancers as well as and the results of clinical trials with this antigen.
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran.
Ali
A
Esfandiary
Soudeh
S
Ghafouri-Fard
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism*; D019496:Cancer Vaccines; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D004938:Esophageal Neoplasms / Q000276:immunology / Q000628:therapy*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007167:Immunotherapy; D008565:Membrane Proteins / Q000276:immunology / Q000378:metabolism*
D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D008565:Membrane Proteins
NY-ESO-1; cancer-testis antigen; immunogenicity; immunotherapy